We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

163 hedge funds and large institutions have $500M invested in Rigel Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 43 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

33% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 43

15% more call options, than puts

Call options by funds: $3.32M | Put options by funds: $2.89M

3% more funds holding

Funds holding: 159 → 163 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.27% less ownership

Funds ownership: 8.32% → 8.05% (-0.27%)

19% less capital invested

Capital invested by funds: $614M → $500M (-$114M)

Holders
163
Holders Change
+4
Holders Change %
+2.52%
% of All Funds
2.85%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
19
Increased
57
Reduced
43
Closed
14
Calls
$3.32M
Puts
$2.89M
Net Calls
+$430K
Net Calls Change
+$606K

Top Buyers

1
HP
HealthInvest Partners
Sweden
+$6.95M
2
LCM
Laurion Capital Management
New York
+$4.43M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.69M
4
TA
Tamarack Advisers
California
+$2.36M
5
DCM
DAFNA Capital Management
California
+$2.22M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$22.2M
2
State Street
State Street
Massachusetts
-$7.85M
3
Wells Fargo
Wells Fargo
California
-$4.4M
4
Millennium Management
Millennium Management
New York
-$2.28M
5
Citigroup
Citigroup
New York
-$1.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$3.86M -$1.34M -34,048 -24%
SCM
27
Sio Capital Management
New York
$3.32M +$330K +8,390 +10%
Charles Schwab
28
Charles Schwab
California
$3.03M +$1.6M +40,656 +95%
DCM
29
DAFNA Capital Management
California
$2.94M +$2.22M +56,500 +232%
CM
30
CM Management
Florida
$2.72M – – –
RCMNY
31
Rubric Capital Management (New York)
New York
$2.41M – – –
PAI
32
Palo Alto Investors
California
$2.37M – – –
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.97M +$118K +3,008 +6%
PAM
34
Panagora Asset Management
Massachusetts
$1.65M -$651K -16,528 -27%
WMSA
35
Weiss Multi-Strategy Advisers
New York
$1.48M +$29.2K +743 +2%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$1.44M -$297K -7,537 -16%
Swiss National Bank
37
Swiss National Bank
Switzerland
$1.35M – – –
Barclays
38
Barclays
United Kingdom
$1.3M +$475K +12,079 +51%
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$1.28M -$48.4K -1,229 -4%
Two Sigma Investments
40
Two Sigma Investments
New York
$1.25M -$607K -15,420 -31%
Squarepoint
41
Squarepoint
New York
$1.23M +$307K +7,805 +30%
AG
42
Artal Group
Luxembourg
$1.17M – – –
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$1.12M – – –
Bank of America
44
Bank of America
North Carolina
$1.09M +$12.4K +316 +1%
Rafferty Asset Management
45
Rafferty Asset Management
New York
$1.07M -$459K -11,658 -28%
BGIM
46
Brandywine Global Investment Management
Pennsylvania
$937K +$1.02M +25,812 New
Los Angeles Capital Management
47
Los Angeles Capital Management
California
$913K -$92.8K -2,358 -9%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$839K -$18.1K -461 -2%
PPA
49
Parametric Portfolio Associates
Washington
$821K -$51.9K -1,318 -6%
SGI
50
Summit Global Investments
Utah
$801K -$12.2K -310 -1%
1
2
3 4 5

RIGL Hedge Fund Activity: Q3 2021 in Review

163 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2021, worth a combined $500M — down 19% from $614M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RIGL positions and 14 closed out — a net gain of 5 holders — while 57 added to existing stakes and 43 trimmed.

The largest buyer was HealthInvest Partners, opening a new position worth an estimated $6.95M. The largest seller was Wellington Management Group, cutting an estimated $22.2M.

  • 163 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2021, up from 159 in Q2 2021.
  • Funds reported $500M of Rigel Pharmaceuticals stock for Q3 2021, down 19% quarter-over-quarter.
  • 19 funds opened new Rigel Pharmaceuticals positions in Q3 2021 and 14 closed out, a net change of +5 holders.
  • The largest Rigel Pharmaceuticals buyer in Q3 2021 was HealthInvest Partners, an estimated $6.95M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2021 was Wellington Management Group, an estimated $22.2M sold.

Based on aggregated 13F filings for Q3 2021.